From: Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Lesion Subtype
Percentage Filled
Cystic
0%
Pre-papillary
0%< x < 25%
Papillary
25% ≤ x < 100%
Solid
100%